

References:

1. Cornely OA, Hoenigl M, Lass-Flörl C, et al. Defining Breakthrough Invasive Fungal Infection— Position Paper of the Mycoses Study Group Education and Research Consortium (MSG-ERC) and the European Confederation of Medical Mycology (ECMM). *Mycoses*. 2019;62(9):716. doi:10.1111/MYC.12960
2. Jenks JD, Cornely OA, Chen SCA, Thompson GR, Hoenigl M. Breakthrough invasive fungal infections: Who is at risk? *Mycoses*. 2020;63(10):1021-1032. doi:10.1111/MYC.13148
3. Vazquez L. Antifungal Prophylaxis in Immunocompromised Patients. *Mediterr J Hematol Infect Dis*. 2016;8(1). doi:10.4084/MJHID.2016.040
4. Jackson M, Cairns T. Care of the critically ill patient. *Surg (United Kingdom)*. 2021;39(1). doi:10.1016/j.mpsur.2020.11.002
5. Larcher R, Platon L, Amalric M, et al. Emerging Invasive Fungal Infections in Critically Ill Patients: Incidence, Outcomes and Prognosis Factors, a Case-Control Study. *J fungi (Basel, Switzerland)*. 2021;7(5). doi:10.3390/JOF7050330
6. Guto JA, Bii CC, Denning DW. Estimated burden of fungal infections in Kenya. *J Infect Dev Ctries*. 2016;10(8):777-784. doi:10.3855/JIDC.7614
7. Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: Epidemiology, diagnosis, and treatment. *Med Mycol*. 2007;45(4). doi:10.1080/13693780701218689
8. Paramythiotou E, Frantzeskaki F, Flevari A, Armaganidis A. Invasive Fungal Infections in the ICU: How to Approach,. Published online 2014:1085-1119. doi:10.3390/molecules19011085
9. Vaillant AAJ, Qurie A. Immunodeficiency. *StatPearls*. Published online July 2022.
10. Lanternier F, Cypowyj S, Picard C, et al. Primary immunodeficiencies underlying fungal infections. *Curr Opin Pediatr*. 2013;25(6). doi:10.1097/MOP.0000000000000031
11. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases—estimate precision. *J Fungi*. 2017;3(4). doi:10.3390/jof3040057
12. Mei-Sheng Riley M. Invasive Fungal Infections Among Immunocompromised Patients in Critical Care Settings: Infection Prevention Risk Mitigation. *Crit Care Nurs Clin North Am*. 2021;33(4):395-405. doi:10.1016/J.CNC.2021.07.002
13. Karavalakis G, Yannaki E, Papadopoulou A. Reinforcing the Immunocompromised Host Defense against Fungi: Progress beyond the Current State of the Art. *J Fungi 2021, Vol 7, Page 451*. 2021;7(6):451. doi:10.3390/JOF7060451
14. Schmidt S, Hogardt M, Demir A, Röger F, Lehnbecher T. Immunosuppressive Compounds Affect the Fungal Growth and Viability of Defined Aspergillus Species. *Pathogens*. 2019;8(4). doi:10.3390/PATHOGENS8040273
15. Patients - Hematology.org.
16. Blood Disorders - Hematology.org.
17. Prophylaxis of invasive fungal infections in adults with hematologic malignancies - UpToDate.

18. Shariati A, Moradabadi A, Chegini Z, Khoshbayan A, Didehdar M. An overview of the management of the most important invasive fungal infections in patients with blood malignancies. *Infect Drug Resist.* 2020;13:2329-2354. doi:10.2147/IDR.S254478
19. Shoham S, Marr KA. Invasive fungal infections in solid organ transplant recipients. *Future Microbiol.* 2012;7(5):639. doi:10.2217/FMB.12.28
20. Rinaldi M, Bartoletti M, Ferrarese A, et al. Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study. *Transpl Infect Dis.* 2021;23(4). doi:10.1111/TID.13608